Derek Thomas O'hagan
#135,645
Most Influential Person Now
Derek Thomas O'hagan's AcademicInfluence.com Rankings
Derek Thomas O'haganbiology Degrees
Biology
#9274
World Rank
#12460
Historical Rank
Immunology
#553
World Rank
#571
Historical Rank

Download Badge
Biology
Derek Thomas O'hagan's Degrees
- Bachelors Biology University of California, Berkeley
Similar Degrees You Can Earn
Why Is Derek Thomas O'hagan Influential?
(Suggest an Edit or Addition)Derek Thomas O'hagan's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome (2009) (519)
- Advances in vaccine adjuvants (1999) (498)
- Cationic microparticles: A potent delivery system for DNA vaccines. (2000) (472)
- Nonviral delivery of self-amplifying RNA vaccines (2012) (465)
- Molecular and cellular signatures of human vaccine adjuvants (2008) (451)
- Recent advances in the discovery and delivery of vaccine adjuvants (2003) (412)
- Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. (2011) (370)
- Emerging concepts in the science of vaccine adjuvants (2021) (327)
- Recent developments in adjuvants for vaccines against infectious diseases. (2001) (320)
- The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells1 (2008) (292)
- Biodegradable microparticles as controlled release antigen delivery systems. (1991) (277)
- Recent Advances in Vaccine Adjuvants (2002) (275)
- The path to a successful vaccine adjuvant--'the long and winding road'. (2009) (268)
- MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection (2007) (252)
- The history of MF59® adjuvant: a phoenix that arose from the ashes (2013) (249)
- A cationic nanoemulsion for the delivery of next-generation RNA vaccines. (2014) (230)
- The Preparation and Characterization of Poly(lactide-co-glycolide) Microparticles. II. The Entrapment of a Model Protein Using a (Water-in-Oil)-in-Water Emulsion Solvent Evaporation Technique (1993) (228)
- Microparticles as vaccine adjuvants and delivery systems (2003) (220)
- Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want (2018) (206)
- The preparation and characterisation of poly(lactide-co-glycolide) microparticles. I: Oil-in-water emulsion solvent evaporation (1991) (199)
- Recent advances in veterinary vaccine adjuvants. (2003) (196)
- Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. (1994) (190)
- Adjuvanting a subunit COVID-19 vaccine to induce protective immunity (2021) (188)
- Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant (2009) (185)
- Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. (2008) (183)
- Enhancement of DNA vaccine potency in rhesus macaques by electroporation. (2004) (182)
- Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines (2001) (180)
- Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. (1993) (180)
- Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. (1992) (178)
- Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. (1995) (173)
- Microparticle-based technologies for vaccines. (2006) (171)
- Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88 (2011) (168)
- Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells (2000) (164)
- The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. (2013) (155)
- Controlled release microparticles for vaccine development. (1991) (153)
- The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells (2009) (153)
- Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake (2017) (152)
- Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus (2015) (151)
- Novel Approaches to Vaccine Delivery (2004) (150)
- Rational design of small molecules as vaccine adjuvants (2014) (149)
- Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. (1996) (149)
- Novel Delivery Systems for Oral Vaccines (1994) (143)
- Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits, and Unrelated Adjuvants (2000) (138)
- The vaccine adjuvant alum inhibits IL‐12 by promoting PI3 kinase signaling while chitosan does not inhibit IL‐12 and enhances Th1 and Th17 responses (2012) (137)
- Biodegradable microparticles for oral immunization. (1993) (136)
- A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. (2001) (135)
- Microparticles for the delivery of DNA vaccines (2004) (134)
- New generation adjuvants--from empiricism to rational design. (2015) (133)
- Mechanism of action of mRNA-based vaccines (2017) (132)
- MF59 adjuvant: the best insurance against influenza strain diversity (2011) (131)
- Designing and building the next generation of improved vaccine adjuvants. (2014) (130)
- Vaccine adjuvants : preparation methods and research protocols (2000) (130)
- Vaccine adjuvant formulations: a pharmaceutical perspective. (2013) (128)
- Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine. (1990) (128)
- Intestinal translocation of particulates — implications for drug and antigen delivery (1990) (122)
- Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. (2006) (122)
- Cationic Microparticles Are an Effective Delivery System for Immune Stimulatory CpG DNA (2001) (121)
- Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. (2000) (119)
- The long-term potential of biodegradable poly(lactideco-glycolide) microparticles as the next-generation vaccine adjuvant (2011) (117)
- CpG Oligodeoxynucleotides Adsorbed onto Polylactide-Co-Glycolide Microparticles Improve the Immunogenicity and Protective Activity of the Licensed Anthrax Vaccine (2005) (116)
- Mucosal adjuvants and delivery systems for protein‐, DNA‐ and RNA‐based vaccines (2004) (115)
- Microparticles as potentially orally active immunological adjuvants. (1989) (113)
- Comparison of poly(DL-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. (1993) (113)
- Microparticles for intranasal immunization. (2001) (112)
- The preparation and characterization ofpoly(lactide-co-glycolide) microparticles: III. Microparticle/polymer degradation rates and the in vitro release of a model protein (1994) (112)
- Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells (1999) (105)
- Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine (2001) (105)
- Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. (2012) (103)
- Delivery systems and adjuvants for oral vaccines (2006) (101)
- The intestinal uptake of particles and the implications for drug and antigen delivery. (1996) (98)
- Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. (1997) (95)
- Investigation of the nasal absorption of biosynthetic human growth hormone in sheep—use of a bioadhesive microsphere delivery system (1990) (94)
- A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. (2006) (94)
- Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. (1995) (90)
- Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. (1995) (89)
- MF59 Is a Safe and Potent Vaccine Adjuvant for Flu Vaccines in Humans: What Did We Learn During Its Development? (2007) (89)
- Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine (1997) (87)
- The identification of plant lectins with mucosal adjuvant activity (2001) (85)
- The impact of size on particulate vaccine adjuvants. (2014) (85)
- Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. (2009) (85)
- Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. (1997) (85)
- Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. (1997) (84)
- Microparticulate absorption from the rat intestine (1994) (84)
- Cationic microparticles are a potent delivery system for a HCV DNA vaccine. (2004) (83)
- A practical approach to the use of nanoparticles for vaccine delivery. (2006) (83)
- Mucosal immunogenicity of plant lectins in mice (2000) (83)
- Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene (2006) (83)
- MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020) (2009) (82)
- Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. (2001) (79)
- Towards an evidence based approach for the development of adjuvanted vaccines. (2017) (79)
- Conference Science Medal Lecture: Recent Advances in Vaccine Adjuvants for Systemic and Mucosal Administration * (1998) (79)
- A comparison of anionic nanoparticles and microparticles as vaccine delivery systems (2008) (79)
- Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. (2013) (78)
- Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. (2004) (77)
- A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. (2002) (76)
- Enhanced Potency of Plasmid DNA Microparticle Human Immunodeficiency Virus Vaccines in Rhesus Macaques by Using a Priming-Boosting Regimen with Recombinant Proteins (2005) (76)
- Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. (2003) (76)
- Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. (2017) (74)
- Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immunization. (1989) (73)
- Targeting of drugs and vaccines to the gut. (1994) (72)
- Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization (2015) (72)
- Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection. (2020) (71)
- Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. (2006) (70)
- Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection (1996) (69)
- Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. (2001) (69)
- The Preparation, Characterization, and Evaluation of Cationic Microparticles for DNA Vaccine Delivery (2001) (69)
- Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles (2003) (63)
- Intranasal Immunization of Mice with Influenza Vaccine in Combination with the Adjuvant LT-R72 Induces Potent Mucosal and Serum Immunity Which Is Stronger than That with Traditional Intramuscular Immunization (1999) (63)
- Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. (1993) (61)
- Controlled release of recombinant insulin-like growth factor from a novel formulation of polylactide-co-glycolide microparticles. (2001) (61)
- Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. (2004) (60)
- Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations (2003) (58)
- The safety of vaccines (2004) (57)
- An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles. (2005) (57)
- Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines (2021) (56)
- Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. (2004) (56)
- The Effect of CTAB Concentration in Cationic PLG Microparticles on DNA Adsorption and in Vivo Performance (2003) (56)
- The continued advance of vaccine adjuvants - 'we can work it out'. (2020) (54)
- Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models. (1998) (52)
- A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. (1998) (52)
- Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines (2021) (52)
- Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. (2003) (52)
- The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. (2008) (52)
- Charged polylactide co-glycolide microparticles as antigen delivery systems (2004) (51)
- Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. (2006) (51)
- Intestinal absorption of proteins and macromolecules and the immunological response. (1988) (51)
- Adsorption of a Novel Recombinant Glycoprotein from HIV (Env gp120dV2 SF162) to Anionic PLG Microparticles Retains the Structural Integrity of the Protein, Whereas Encapsulation in PLG Microparticles Does Not (2004) (50)
- A comparison of alternative methods for the determination of the levels of proteins entrapped in poly(lactide-co-glycolide) microparticles (1995) (49)
- Recent developments in vaccine delivery systems. (2001) (48)
- Oral Delivery of Vaccines (1992) (45)
- Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations. (2012) (45)
- Nasal Absorption Enhancers for Biosynthetic Human Growth Hormone in Rats (1990) (44)
- The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility. (1997) (43)
- Characterization of Human Immunodeficiency Virus Gag-Specific Gamma Interferon-Expressing Cells following Protective Mucosal Immunization with Alphavirus Replicon Particles (2005) (43)
- Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae. (1995) (43)
- Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. (2000) (42)
- Zero order release of protein from poly(d,l-lactide-co-glycolide) microparticles prepared using a modified phase separation technique (1995) (42)
- The development of self-emulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance. (2015) (41)
- Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses. (2014) (41)
- Genetically detoxified mutants of heat‐labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T‐cell responses against HIV‐1 gag‐p55 (2000) (41)
- MF59: A Safe and Potent Adjuvant for Human Use (2006) (40)
- Novel approaches to pediatric vaccine delivery. (2006) (40)
- Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. (2002) (39)
- Mannosylation of LNP results in improved potency for self-amplifying RNA (SAM) vaccines. (2019) (38)
- The immunogenicity of a model protein entrapped in poly(lactide-co-glycolide) microparticles prepared by a novel phase separation technique (1994) (37)
- Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. (2017) (37)
- Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. (1996) (36)
- Oral Administration of Influenza Vaccine in Combination with the Adjuvants LT-K63 and LT-R72 Induces Potent Immune Responses Comparable to or Stronger than Traditional Intramuscular Immunization (2001) (35)
- Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines (2016) (35)
- Immunological Implications of the use of Plant Lectins for Drug and Vaccine Targeting to the Gastrointestinal Tract (2004) (35)
- Recent developments in vaccine delivery systems (2001) (35)
- An alternative renewable source of squalene for use in emulsion adjuvants. (2011) (34)
- Protection of Rhesus Monkeys by a DNA Prime/Poxvirus Boost Malaria Vaccine Depends on Optimal DNA Priming and Inclusion of Blood Stage Antigens (2007) (33)
- Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines. (2021) (33)
- MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine (2012) (32)
- Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. (1999) (32)
- The preparation, characterization and pre-clinical evaluation of an orally administered HIV-I vaccine, consisting of a branched peptide immunogen entrapped in controlled release microparticles (1995) (31)
- Effect of L-α-lysophosphatidylcholine on the nasal absorption of human growth hormone in three animal species (1991) (31)
- Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant. (2001) (31)
- Flow cytometry: an alternative method for direct quantification of antigens adsorbed to aluminum hydroxide adjuvant. (2011) (31)
- Development of a potent Zika virus vaccine using self-amplifying messenger RNA (2020) (30)
- Innate immunity and biodefence vaccines (2003) (30)
- Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model. (2014) (30)
- Combination Vaccines (2011) (29)
- Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin. (1993) (29)
- Rational Design of Adjuvant for Skin Delivery: Conjugation of Synthetic β-Glucan Dectin-1 Agonist to Protein Antigen. (2015) (29)
- Controlled release microparticles for oral immunization (1994) (29)
- Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein. (1992) (28)
- Cholera toxin B subunit (CTB) entrapped in microparticles shows comparable immunogenicity to CTB mixed with whole cholera toxin following oral immunization (1995) (28)
- Dose-Dependent Protection against or Exacerbation of Disease by a Polylactide Glycolide Microparticle-Adsorbed, Alphavirus-Based Measles Virus DNA Vaccine in Rhesus Macaques (2008) (27)
- The quantitation of the absorption of microparticles into the intestinal lymph of Wistar rats (1994) (25)
- Bioadhesive delivery systems for mucosal vaccine delivery (2010) (25)
- A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. (2007) (24)
- Are we entering a new age for human vaccine adjuvants? (2015) (23)
- β7‐integrin‐independent enhancement of mucosal and systemic anti‐HIV antibody responses following combined mucosal and systemic gene delivery (2007) (23)
- Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines (2020) (23)
- Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs. (2015) (23)
- Design of a novel vaccine nanotechnology-based delivery system comprising CpGODN-protein conjugate anchored to liposomes. (2020) (23)
- Emulsion-Based Adjuvants for Improved Influenza Vaccines (2011) (22)
- Biodegradable microparticles as oral vaccines. (1995) (22)
- New Generation Vaccine Adjuvants (2015) (21)
- Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide. (2016) (21)
- The droplet size of emulsion adjuvants has significant impact on their potency, due to differences in immune cell-recruitment and -activation (2019) (20)
- A modified process for preparing cationic polylactide-co-glycolide microparticles with adsorbed DNA. (2006) (20)
- Characterization of antigens adsorbed to anionic PLG microparticles by XPS and TOF-SIMS. (2008) (20)
- A two-stage strategy for sterilization of poly(lactide-co-glycolide) particles by γ-irradiation does not impair their potency for vaccine delivery. (2011) (19)
- Biodegradable microparticles as a delivery system for the allergens of Dermatophagoides pteronyssinus (house dust mite): I. Preparation and characterization of microparticles (1995) (19)
- Emulsions as Vaccine Adjuvants (2015) (19)
- Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. (2006) (19)
- Oral immunization with poly(lactide-co-glycolide) microparticles containing an entrapped recombinant glycoprotein (gD2) from herpes simplex type 2 virus (1998) (19)
- Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination. (2008) (18)
- Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates (2021) (18)
- “World in motion” – emulsion adjuvants rising to meet the pandemic challenges (2021) (17)
- Gaps in knowledge and prospects for research of adjuvanted vaccines. (2015) (17)
- Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63). (2002) (17)
- Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88. (2008) (17)
- The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine. (2016) (16)
- The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A. (2015) (16)
- Adsorption onto aluminum hydroxide adjuvant protects antigens from degradation. (2020) (16)
- Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice (2009) (15)
- Recent advances in immunological adjuvants: the development of particulate antigen delivery systems. (1998) (15)
- Multiplex immunoassay for in vitro characterization of acellular pertussis antigens in combination vaccines. (2016) (14)
- Novel adjuvants and delivery systems for HIV vaccines (2002) (14)
- Combinations of protein polysaccharide conjugate vaccines for intranasal immunization. (2002) (14)
- Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine (2022) (14)
- Adjuvants: progress, regress and pandemic preparedness (2007) (14)
- Microparticles as vaccine delivery systems (2006) (14)
- The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency (2021) (13)
- Rational design of adjuvants for subunit vaccines: The format of cationic adjuvants affects the induction of antigen-specific antibody responses. (2020) (13)
- Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want (2018) (13)
- Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine. (2019) (13)
- Emulsion based vaccine adjuvants (2013) (12)
- The preparation and characterization of PLG nanoparticles with an entrapped synthetic TLR7 agonist and their preclinical evaluation as adjuvant for an adsorbed DTaP vaccine. (2016) (12)
- Comparison of Poly(dl-Lactide-co-glycolide) and Polystyrene Microsphere Targeting to Intestinal M Cells (2003) (12)
- MF59: A Safe and Potent Oil‐in‐Water Emulsion Adjuvant (2006) (11)
- HIV and mucosal immunity (1991) (11)
- Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines (2020) (11)
- Formulation Design, Optimization and In Vivo Evaluations of an α-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine. (2019) (10)
- Biodegradable microparticles with an entrapped branched octameric peptide as a controlled-release HIV-1 vaccine. (1997) (10)
- Stable Nanoemulsions for the Delivery of Small Molecule Immune Potentiators. (2018) (10)
- Chapter 13 – MF59: A Safe and Potent Adjuvant for Human Use (2017) (9)
- Optimizing gastrointestinal delivery of drugs. (1994) (9)
- Antigen Delivery Systems I: Nonliving Microparticles, Liposomes, and Immune-Stimulating Complexes (ISCOMs) (2015) (9)
- Mutant Heat-Labile Entertoxins As Adjuvants for CTL Induction (2000) (9)
- Preparation of highly concentrated influenza vaccine for use in novel delivery approaches. (2013) (9)
- Optimizing adjuvants for intradermal delivery of MenC glycoconjugate vaccine. (2017) (8)
- Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines (2021) (8)
- The Preparation and Physicochemical Characterization of Aluminum Hydroxide/TLR7a, a Novel Vaccine Adjuvant Comprising a Small Molecule Adsorbed to Aluminum Hydroxide. (2018) (7)
- Immunopotentiators in Modern Vaccines : Second Edition (2016) (6)
- Adjuvants: from serendipity to rational discovery. (2012) (6)
- Polymeric Particles as Vaccine Delivery Systems (2017) (6)
- Injectable PLGA Systems for Delivery of Vaccine Antigens (2012) (6)
- Synthesis of protein conjugates adsorbed on cationic liposomes surface (2020) (5)
- Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice (2022) (5)
- Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines (2020) (4)
- Surface‐Charged Poly(Lactide‐Co‐Glycolide) Microparticles as Novel Antigen Delivery Systems (2006) (4)
- Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. (2009) (3)
- Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine (2022) (3)
- Non-viral delivery of self-amplifying RNA (2012) (3)
- MF59: A safe and potent oil in water emulsion adjuvant for influenza vaccines, which induces enhanced protection against virus challenge (2008) (3)
- Concepts in Mucosal Immunity and Mucosal Vaccines (2014) (2)
- Novel nonreplicating antigen delivery systems (1990) (2)
- Pharmaceutical formulations as immunological adjuvants (1987) (2)
- Infiltration of dendritic cells and antigen uptake in the muscle after injection of HIV-1 Env gp120 in adjuvant (2012) (1)
- Enhancing and Tailoring the Immunogenicity of Vaccines with Novel Adjuvants (2012) (1)
- Immunogenic compositions comprising microparticles comprising adsorbed toxoid antigen and containing a polysaccharide (2004) (1)
- New developments in nasal vaccine delivery (1999) (1)
- Extent of supercoiling in plasmid DNA vaccines (2006) (1)
- Particulates and Lymphatic Drug Delivery (2019) (1)
- Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice (2022) (1)
- Corrigendum to “The mechanism of action of MF59 – An innately attractive adjuvant formulation” [Vaccine 30 (2012) 4341–4348] (2013) (1)
- Beta7-integrin independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery (41.1) (2007) (1)
- Colloidal carriers as antigen delivery systems for oral immunisation (1990) (1)
- Recent Developments in Nonliving Antigen Delivery Systems (2009) (1)
- Maturation of Aluminium Adsorbed Antigens Contributes to the Creation of Homogeneous Vaccine Formulations (2023) (1)
- Biophysical Characterization of Protein Antigens within Vaccine Formulations (2011) (1)
- Intra-nasal Immunization with Filamentous Haemagglutinin Protects Mice Against Bordetella pertussis Infection (1993) (1)
- Hiv vaccine-and application procedures (2003) (0)
- Use of microparticles with adsorbed antigen for stimulating the immune defenses (1998) (0)
- Compositions de peptides amphipatiques immunogènes (2009) (0)
- Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response. (2022) (0)
- A method for maintaining cell immune responses against proteins (2000) (0)
- Bioadhesives and adjuvants use for the administration of antigens mucosally. (1999) (0)
- A Self-Emulsified Adjuvant System Containing the Immune Potentiator Alpha Tocopherol Induces Higher Neutralizing Antibody Responses than a Squalene-Only Emulsion When Evaluated with a Recombinant Cytomegalovirus (CMV) Pentamer Antigen in Mice (2023) (0)
- Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2 (2023) (0)
- Microparticles and DNA Vaccines (2006) (0)
- Flu shots with reduced amounts of squalene (2010) (0)
- Author Correction: “World in motion” – emulsion adjuvants rising to meet the pandemic challenges (2023) (0)
- Concentration and characterization of influenza antigen bulks for potential novel vaccine delivery applications (2011) (0)
- Adjuvanted influenza vaccines and their potential role for vaccination of travelers (2010) (0)
- Compositions de meningocoque assorties d'un adjuvant (2002) (0)
- Genetic Assessment of B-cell Responses Following Immunization with HIV Env Protein and Adjuvants or SHIV (AD8) Infection in Nonhuman Primates (2014) (0)
- Virionlignende feed particles to self-replicating RNA molecules (2011) (0)
- Overview of vaccine adjuvants (2022) (0)
- VaccineRhesus Macaques by a Nonclassical ISCOM Core-Specific Immune Responses Primed in Characterization of Hepatitis C Virus (2001) (0)
- Microemulsions a macromolecules et microparticules adsorbees (2000) (0)
- Flu vaccines that include combinations of particulate adjuvants and immunopotentiating (2006) (0)
- Vaccine in Rhesus Macaques Alphavirus-Based Measles Virus DNA Glycolide Microparticle-Adsorbed , Exacerbation of Disease by a Polylactide Dose-Dependent Protection against or (2008) (0)
- MRI/PET multimodal imaging of the innate immune response in skeletal muscle and draining lymph node post vaccination in rats (2023) (0)
- Cationic Microparticles and Emulsions As Effective Delivery Systems for Immune Stimulatory CpG DNA (2004) (0)
- Use of polymers of hyaluronic acid for mucosal release of vaccines and adjuvants (1999) (0)
- Particulates and microemulsions with adsorbed microparticles. (2000) (0)
- Use of bioadhesives and adjuvants for mucosal application of antigenic (1999) (0)
- immunogenic compositions based on biodegradable microparticles comprising a diphtheria toxoid and tetanus. (2004) (0)
- Procedure for cellular immune responses proteins. (2000) (0)
- Influenza vaccines containing combinations of particulate adjuvants, and immune enhancers (2006) (0)
- Microparticles comprising polynucleotides adsorbed on the surface of microparticles or trapped inside thereof (2004) (0)
- A process for the production of IGF-I, sustained release formulations (1998) (0)
- “World in motion” – emulsion adjuvants rising to meet the pandemic challenges (2021) (0)
- Conclusions—“Getting Better” (2017) (0)
- Vaccine adjuvants 1 (2015) (0)
- Distinctive innate immune signatures at the injection site predict the adjuvant-mediated boost of adaptive responses towards a flu subunit vaccine. (106.9) (2011) (0)
- Microparticles for administration of heterologous nucleic acid (2001) (0)
- Compositions d'adjuvants (2002) (0)
- Vaccine adjuvants 2 (2015) (0)
- Compositions de microparticules et procede de fabrication desdites compositions (2001) (0)
- Theintestinal uptake ofparticles andtheimplications for drugandantigen delivery (1996) (0)
- Emerging concepts in the science of vaccine adjuvants (2021) (0)
This paper list is powered by the following services: